Australia Medical Industries

Australian Medical Industries (AMI) is a pharmaceutical and biotechnology company based in Greystanes, New South Wales. The company is a manufacturer and supplier of Australian-made pharmaceuticals, therapeutics, and medical consumables, including its well-known personal lubricant brand, L-gel. Beyond its commercial product portfolio, AMI is engaged in drug discovery and development, with a focus on cardiovascular and neurological conditions. Its lead pipeline candidate, LMR-123, is a new molecular entity being evaluated in Phase 1 clinical trials for the treatment of acute ischaemic stroke. The company serves both domestic and international healthcare markets through its manufacturing and distribution capabilities.